Oncology

#Oncology #RNA #Therapeutics

BIA Separations offers bioprocessing technology for the development of advanced therapeutics

18 June 2020 Image:ThisIsEngineering BIA Separations has introduced its novel PrimaS ligand technology. The proprietary multi-use platform faciliates high-resolution and high speed processing and says BIA, addresses many critical separation problems in fast emerging advanced therapy medicinal products (ATMPs). BIA Separations has introduced its novel PrimaS ligand technology. Read More

#News

#Analysis #Biochemistry #Cell therapy #Clinical trials #Gene therapy #Oncology

AstraZeneca presents results from Calquence (acalabrutinib) trials

16 June, 2020 The global science-led biopharmaceutical company said the detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult… Read More

#News

#Cell therapy #Oncology

Faron presents Part I of the Matins trial safety and efficacy results

01 June, 2020 The clinical stage biopharmaceutical company presented the safety and efficacy results from Part I of the Matins trial in a poster at the virtual ASCO20 (American Society of Clinical Oncology) Annual Meeting. During the ASCO poster presentation, Faron Pharmaceuticals said the ongoing phase I/II Matins… Read More

#News

#Business #Cell therapy #Clinical specialities #Clinical trials #Gene therapy #Oncology #Therapeutics

Oxford Biomedica and AstraZeneca sign agreement for Covid-19 vaccine

Gene and cell therapy group Oxford Biomedica has signed a one-year clinical and commercial supply agreement with AstraZeneca for the manufacture of a Covid-19 vaccine candidate. The agreement relates to the GMP manufacture of the adenovirus vector based Covid-19 vaccine candidate, AZD1222, which recently entered clinical trials at… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Cell therapy #Gene therapy #Immunology #Oncology #Preclinical #Therapeutics

Boehringer Ingelheim acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline

18 May, 2020 The research-driven pharmaceutical company said the new acquisition provides assets targeting the tumour stroma and myeloid cells. Boehringer Ingelheim also announced it is collaborating with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, a leading cause of blindness. The first programme, now in late… Read More

#News

#Cell therapy #Clinical specialities #Drug development #Immunology #Immunology / Virology & Vaccines #Oncology #RNA #Stem cells

NanoPass shares Micronjet technology with global partners

The Israel based developer of nearly painless intradermal delivery solutions for vaccines and drugs said it is joining forces with leading vaccine and immunotherapy companies worldwide to share its proprietary MicronJet microneedle device. According to NanoPass, the aim is to enable the development of a safe, effective and… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic… Read More

#Exclusive Content

#Academic #Assay development optimisation & technology #Business #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #RNA #Target validation #Therapeutics

The Reproducibility Crisis – How did we get here?

By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Cancer research #Imaging #Lung cancer #Oncology

CIAN Lung: Exploring the potential of real-world data in lung cancer research

This article is sponsored by BC Platforms. Lung cancer ranks among the most prevalent and fatal cancers worldwide, prompting the need for improved treatment outcomes. Effective management relies on understanding tumour characteristics, including histology, clinical staging, and biomarkers. Despite progress in targeted therapies, ongoing research is… Read More

#News

#Animal models #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 – Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Oncology #PCR #Precision medicine #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Antimicrobial resistance threatens to undermine our healthcare system

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 – Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High throughput screening #Molecular medicine #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Target discovery and drug development what comes after CRISPR?

Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 – Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Reprogramming the stem cell for a new generation of cures

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 – Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering,… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Preclinical #RNA #System biology #Systems biology #Therapeutics

Drug development 2.0 – The partnership model in practice

Drug development 2.0 – The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #PCR #Preclinical #RNA #Therapeutics

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules… Read More

#Archive